Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). It is an orally administered thienopyridine derivative.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with ACS (unstable angina, non-ST-elevation MI, or ST-elevation MI).
* Prevention of thrombotic events in patients with a history of MI.
## Adult Dosing
* **ACS:** An initial loading dose of 180 mg orally once, followed by 90 mg orally twice daily for at least 12 months.
* **History of MI:** 60 mg orally twice daily.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution in patients with severe hepatic impairment. No dose adjustment is recommended.
* **Renal Impairment:** No dose adjustment is recommended.
## Contraindications
* Hypersensitivity to ticagrelor or any of its excipients.
* Active pathological bleeding.
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including fatal and life-threatening), bradycardia.
* **Serious:** Major bleeding, intracranial hemorrhage, ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor concentrations. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor concentrations.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Avoid concomitant use with other potent antiplatelets or anticoagulants unless clinically indicated and with careful monitoring.
* **Statins:** Ticagrelor can increase statin concentrations, particularly simvastatin and atorvastatin. Monitor for statin-related adverse effects.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea.
* Periodically assess for bradycardia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel or prasugrel which are irreversible. This may offer an advantage in patients requiring urgent surgery.
* Dyspnea is a common side effect and is usually not clinically significant. However, it warrants assessment to rule out other causes.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If a drug interruption is necessary, consider bridging therapy if feasible.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to guide patient care. Dosing and management may vary based on individual patient factors and local protocols.*
